FAKTOR-OPTIONSSCHEIN - HALEON Stock

Certificat

DE000MG1K2X1

Real-time Bid/Ask 04:15:14 2024-05-23 am EDT
9.17 EUR / 9.23 EUR -4.56% Intraday chart for FAKTOR-OPTIONSSCHEIN - HALEON
Current month+1.69%
1 month+4.44%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-22 9.64 +4.67%
24-05-21 9.21 +5.62%
24-05-20 8.72 -7.92%
24-05-17 9.47 +1.18%
24-05-16 9.36 +0.86%

Delayed Quote Börse Stuttgart

Last update May 22, 2024 at 05:22 am EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying HALEON PLC
Issuer Morgan Stanley
WKN MG1K2X
ISINDE000MG1K2X1
Date issued 2024-04-03
Strike 386.8 p
Maturity Unlimited
Parity 0.07 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 12.4
Lowest since issue 8.72
Spread 0.06
Spread %0.64%

Company Profile

Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Sector
-
More about the company

Ratings for Haleon plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Haleon plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.311 GBP
Average target price
3.62 GBP
Spread / Average Target
+9.33%
Consensus